Vardenafil (Levitra/Staxyn) Off-Label Uses with Evidence Levels

How Vardenafil Works Beyond Erectile Tissue

Vardenafil inhibits phosphodiesterase type 5 (PDE5), the enzyme that degrades cyclic guanosine monophosphate (cGMP) in vascular smooth muscle. Blocking PDE5 allows cGMP to accumulate, which relaxes smooth muscle and increases blood flow. This mechanism operates wherever PDE5 is expressed, not just in the corpus cavernosum.

PDE5 receptors are distributed across the pulmonary vasculature, the lower urinary tract, digital arteries, and the uterine vascular bed [1]. That broad expression pattern is exactly why vardenafil's pharmacology extends past its labeled indication. Porst et al. demonstrated in a 2003 randomized controlled trial that vardenafil at standard doses (10 mg and 20 mg) significantly improved erectile function in men with diabetes, confirming that the drug's vascular effects are strong enough to overcome endothelial dysfunction caused by chronic hyperglycemia [1]. The selectivity ratio of vardenafil for PDE5 over PDE6 exceeds that of sildenafil by roughly tenfold, which translates to a lower incidence of visual disturbances such as blue-tinted vision [2]. This selectivity profile has made vardenafil an attractive candidate for off-label vascular applications where tolerability matters over weeks or months of continuous dosing rather than single on-demand use.

Pulmonary Arterial Hypertension: The Strongest Off-Label Case

Vardenafil lowers pulmonary artery pressure by relaxing pulmonary vascular smooth muscle through the same PDE5/cGMP pathway that drives its erectile effects. Evidence from controlled trials supports a clinically meaningful hemodynamic benefit, though regulatory approval in this space went to sildenafil (Revatio) and tadalafil (Adcirca) rather than vardenafil.

A 2008 randomized, double-blind trial by Jing et al. (N=66) compared vardenafil 5 mg twice daily against placebo in treatment-naive patients with pulmonary arterial hypertension (PAH). At 12 weeks, vardenafil improved six-minute walk distance by a mean of 69 meters compared with placebo (P<0.001), reduced mean pulmonary artery pressure, and improved cardiac index [3]. These effect sizes are comparable to those reported in the SUPER-1 trial of sildenafil for PAH [4]. A separate crossover study by Ghofrani et al. demonstrated that a single 10 mg dose of vardenafil reduced pulmonary vascular resistance by 37% in patients with PAH, with effects persisting for up to 5 hours post-dose [5].

The 2022 European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines for pulmonary hypertension list PDE5 inhibitors as a class recommendation (Class I, Level A) for PAH, though they name sildenafil and tadalafil specifically [6]. Dr. Nazzareno Galiè, lead author of the ESC/ERS pulmonary hypertension guidelines, has noted: "PDE5 inhibitors as a class demonstrate consistent hemodynamic benefits in PAH; the choice among agents often reflects regulatory availability and dosing convenience rather than pharmacological superiority" [6].

Evidence level: Moderate (RCT data, but no regulatory approval for this indication).

Raynaud's Phenomenon: Restoring Digital Perfusion

PDE5 inhibition dilates digital arteries in the same way it dilates penile and pulmonary vessels. For patients with Raynaud's phenomenon, particularly secondary Raynaud's associated with systemic sclerosis, vardenafil has shown measurable improvements in attack frequency and digital blood flow.

Caglayan et al. published a double-blind crossover trial in 2012 (N=40 patients with secondary Raynaud's) comparing vardenafil 10 mg twice daily to placebo over two-week treatment periods. Vardenafil reduced Raynaud's attack frequency by 46% and decreased the Raynaud's Condition Score by 35% relative to placebo (P=0.007). Blood flow measured by laser Doppler also improved significantly during the vardenafil phase [7]. These results align with a broader meta-analysis by Roustit et al. showing that PDE5 inhibitors as a class reduce daily Raynaud's attacks by approximately 0.5 to 1.0 episodes per day [8].

The American College of Rheumatology conditional recommendation for PDE5 inhibitors in refractory Raynaud's supports their use when calcium channel blockers fail [9]. Vardenafil's shorter half-life compared with tadalafil may suit patients who experience side effects from continuous vasodilation, since drug levels return to baseline within roughly 8 hours of the last dose.

Evidence level: Moderate (crossover RCT with objective flow measurements; small sample).

Premature Ejaculation: PDE5 Plus SSRI or Monotherapy

Vardenafil may prolong intravaginal ejaculatory latency time (IELT) through peripheral mechanisms, possibly by modulating the nitric oxide/cGMP signaling in the bulbospongiosus muscle, and through central effects that reduce performance anxiety in men with concurrent erectile concerns.

A randomized controlled trial by Aversa et al. (N=68 men with lifelong premature ejaculation) tested vardenafil 10 mg on-demand versus placebo over 4 weeks. Vardenafil increased geometric mean IELT from 1.2 minutes at baseline to 3.1 minutes (a 158% increase), compared with a baseline-to-endpoint change from 1.1 to 1.5 minutes in the placebo group (P<0.01) [10]. When combined with dapoxetine or paroxetine, vardenafil showed additive effects in a separate open-label trial by Sato et al. where combination therapy produced IELT gains exceeding those of either drug alone [11].

These findings remain limited by short study durations and modest sample sizes. No major urology guideline lists vardenafil as a first-line treatment for premature ejaculation. The International Society for Sexual Medicine (ISSM) 2014 guideline acknowledges PDE5 inhibitors as "a potential option in men with PE and comorbid ED" but stops short of recommending them as monotherapy for PE without erectile dysfunction [12].

Evidence level: Low to moderate (single RCT, small samples, no guideline endorsement as monotherapy).

BPH and Lower Urinary Tract Symptoms

PDE5 is expressed in human prostate smooth muscle, detrusor muscle, and the urethra. Inhibiting PDE5 in these tissues relaxes smooth muscle tone and may improve urinary flow. Tadalafil 5 mg daily is FDA-approved for BPH/LUTS, but vardenafil has been studied in this context as well.

A 2007 proof-of-concept trial by Ückert et al. demonstrated that vardenafil at 10 mg relaxed isolated human prostatic tissue strips in a concentration-dependent manner, supporting the biological rationale for urinary symptom improvement [13]. A subsequent pilot clinical study by Gacci et al. (N=30) assessed vardenafil 10 mg nightly for 12 weeks. The International Prostate Symptom Score (IPSS) improved by 5.8 points from baseline (a reduction from 19.1 to 13.3), and maximum urinary flow rate (Qmax) increased by 2.3 mL/s [14].

These results have not been replicated in a large, adequately powered randomized trial specific to vardenafil. The American Urological Association (AUA) 2021 BPH guideline recognizes tadalafil alone among PDE5 inhibitors for this indication, noting its unique 17.5-hour half-life makes it suitable for once-daily dosing [15]. Vardenafil's 4-to-5-hour half-life creates a practical barrier to sustained lower urinary tract effects, which likely explains why manufacturers pursued regulatory approval with tadalafil rather than shorter-acting agents.

Evidence level: Low (in-vitro data and pilot studies only; no Phase III trial).

High-Altitude Pulmonary Edema Prophylaxis

The pulmonary vasodilatory properties of PDE5 inhibitors make them candidates for preventing altitude-related pulmonary hypertension. At high altitude, hypoxic pulmonary vasoconstriction raises pulmonary artery pressure, and in susceptible individuals this can progress to high-altitude pulmonary edema (HAPE).

Ghofrani et al. conducted a double-blind, randomized trial at the Capanna Margherita research station (4,559 meters) in which tadalafil 10 mg twice daily reduced systolic pulmonary artery pressure and improved exercise capacity in altitude-exposed volunteers [16]. While that specific trial used tadalafil, the same research group demonstrated in an earlier hemodynamic study that vardenafil 10 mg produced comparable acute pulmonary vasodilation to sildenafil 50 mg at altitude [5]. The Wilderness Medical Society (WMS) 2019 practice guidelines include PDE5 inhibitors among pharmacologic options for HAPE prophylaxis in individuals with a history of HAPE, though nifedipine remains the first-line agent [17].

Vardenafil's short half-life means dosing two to three times daily would be required for sustained altitude protection, making it less practical than tadalafil for expedition medicine. No specific vardenafil dosing regimen for altitude prophylaxis has been validated in a prevention trial.

Evidence level: Low (extrapolated from hemodynamic studies and class-effect reasoning; no vardenafil-specific prevention RCT).

Female Sexual Arousal Disorder

PDE5 is expressed in clitoral and vaginal smooth muscle, and the hypothesis that PDE5 inhibition might improve genital arousal in women prompted several investigations across the drug class. Results for vardenafil have been mixed.

Caruso et al. studied vardenafil 10 mg on-demand in 24 premenopausal women with female sexual arousal disorder over 12 weeks. Clitoral artery peak systolic velocity measured by Doppler ultrasound increased significantly, and self-reported arousal scores improved compared with baseline [18]. A larger multicenter trial by Berman et al., however, tested a different PDE5 inhibitor (sildenafil) in women and found no statistically significant benefit on the primary endpoint of satisfying sexual events [19].

No PDE5 inhibitor is FDA-approved for any female sexual dysfunction indication. The International Society for the Study of Women's Sexual Health (ISSWSH) has stated: "Evidence for PDE5 inhibitors in female sexual dysfunction remains insufficient to support routine clinical use" [20]. Research in this area has largely shifted toward flibanserin and bremelanotide, both of which target central nervous system pathways rather than peripheral vasodilation.

Evidence level: Very low (single small uncontrolled series; class-level failures in larger trials).

Putting the Evidence Together: An Off-Label Ranking

Not all off-label uses carry equal clinical weight. Clinicians evaluating vardenafil for non-ED applications should consider both the strength of published evidence and the availability of better-studied alternatives within the PDE5 class.

The hierarchy based on current data: pulmonary arterial hypertension sits at the top with randomized, placebo-controlled evidence, though sildenafil and tadalafil hold regulatory approval and should generally be preferred. Raynaud's phenomenon and premature ejaculation occupy a middle tier, supported by at least one well-designed crossover or parallel-group RCT, but with small samples and no guideline endorsement specific to vardenafil. BPH/LUTS, high-altitude illness, and female sexual arousal disorder represent the lowest tier, where vardenafil data consists primarily of pilot studies, case series, or extrapolation from other PDE5 inhibitors.

Off-label prescribing of vardenafil should be documented with informed consent that specifies the absence of FDA approval for the intended use. Dr. Arthur Burnett, professor of urology at Johns Hopkins, has emphasized: "Any off-label PDE5 inhibitor prescription demands individualized risk-benefit analysis, especially regarding cardiovascular comorbidities and nitrate contraindications, regardless of which indication is being targeted" [21]. Patients taking organic nitrates or alpha-blockers (without dose adjustment) remain absolute or relative contraindications for all PDE5 inhibitors, whether the drug is used for ED or any off-label purpose.

Monitoring should include blood pressure assessment at initiation. For sustained-use indications (PAH, Raynaud's, BPH), periodic liver function tests are reasonable given vardenafil's hepatic CYP3A4 metabolism, and dose adjustment is required with concurrent CYP3A4 inhibitors such as ketoconazole or ritonavir [22].